Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.08.345
Abirami Kirubarajan M.D., M.Sc. , Nazmul Sohel Ph.D. , Alexandra Mayhew Ph.D. , Lauren E. Griffith Ph.D. , Parminder Raina Ph.D. , Alison K. Shea M.D., Ph.D.
<div><h3>Objective</h3><div>To describe the prevalence of multimorbidity among individuals with primary ovarian insufficiency (POI) and early menopause compared with those with the average age of menopause.</div></div><div><h3>Design</h3><div>Prospective cohort.</div></div><div><h3>Subjects</h3><div>This prospective cohort encompassed female postmenopausal individuals from the Canadian Longitudinal Study on Aging. The Canadian Longitudinal Study on Aging collected cross-sectional data from 50,000 community-dwelling Canadians aged 45–85 years between 2010 and 2015.</div></div><div><h3>Exposure</h3><div>The primary exposure was POI (defined by onset of menopause at the age of <40 years). Comparators included average age of menopause (age, 46–55 years), early menopause (40–45 years), and late-onset menopause (56–65 years) and those who underwent hysterectomy.</div></div><div><h3>Main Outcome Measure(s)</h3><div>The primary outcome was multimorbidity, which was defined as two or more chronic conditions. The secondary outcomes were severe multimorbidity (defined as 3 or more chronic conditions) and frequencies of specific chronic conditions among a comprehensive list of 15 individual conditions. We assessed the association between multimorbidity and age at menopause using logistic regression and odds ratios (ORs), with confidence intervals (CIs) set at 95%. The ORs were adjusted for known predictors of multimorbidity, including age, menopausal hormone therapy, education, ethnicity, self-reported loneliness, living alone, body mass index, smoking habits, nutritional risk, social participation, and physical activity.</div></div><div><h3>Result(s)</h3><div>A total of 12,339 postmenopausal participants were included, of whom 374 (3.0%) experienced POI and 1,396 (11.3%) experienced early menopause. The prevalence rates of multimorbidity were 64.8% and 51.1% among those with POI and early menopause, respectively. In contrast, only 43.9% of individuals with average age of menopause (age, 46–55 years) had multimorbidity. The OR for multimorbidity in the POI population was 2.5 (95% CI, 2.0–3.1) compared with that in individuals who had the average age of menopause. This relationship was maintained after adjustment for confounders (adjusted OR [aOR], 2.0; 95% CI, 1.5–2.5). The prevalence of severe multimorbidity was also double in the POI group compared with that in the average age group (39.2% vs. 21.1%). There were significantly increased risks of ischemic heart disease (aOR, 2.8; 95% CI, 1.7–4.7), gastric ulcers (aOR, 1.6; 95% CI, 1.1–2.3), and osteoporosis (aOR, 1.6; 95% CI, 1.2–2.1) in the POI group.</div></div><div><h3>Conclusion(s)</h3><div>Individuals with POI and early menopause experience increased multimorbidity compared with those undergoing menopause at an average age. This trend persists even after adjusting for significant multimorbidity risk factors.</div></div><div><div>Asociación entre insuficiencia ovárica primaria y incremento en la multi
{"title":"The association between primary ovarian insufficiency and increased multimorbidity in a large prospective cohort (Canadian Longitudinal Study on Aging)","authors":"Abirami Kirubarajan M.D., M.Sc. , Nazmul Sohel Ph.D. , Alexandra Mayhew Ph.D. , Lauren E. Griffith Ph.D. , Parminder Raina Ph.D. , Alison K. Shea M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.08.345","DOIUrl":"10.1016/j.fertnstert.2024.08.345","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the prevalence of multimorbidity among individuals with primary ovarian insufficiency (POI) and early menopause compared with those with the average age of menopause.</div></div><div><h3>Design</h3><div>Prospective cohort.</div></div><div><h3>Subjects</h3><div>This prospective cohort encompassed female postmenopausal individuals from the Canadian Longitudinal Study on Aging. The Canadian Longitudinal Study on Aging collected cross-sectional data from 50,000 community-dwelling Canadians aged 45–85 years between 2010 and 2015.</div></div><div><h3>Exposure</h3><div>The primary exposure was POI (defined by onset of menopause at the age of <40 years). Comparators included average age of menopause (age, 46–55 years), early menopause (40–45 years), and late-onset menopause (56–65 years) and those who underwent hysterectomy.</div></div><div><h3>Main Outcome Measure(s)</h3><div>The primary outcome was multimorbidity, which was defined as two or more chronic conditions. The secondary outcomes were severe multimorbidity (defined as 3 or more chronic conditions) and frequencies of specific chronic conditions among a comprehensive list of 15 individual conditions. We assessed the association between multimorbidity and age at menopause using logistic regression and odds ratios (ORs), with confidence intervals (CIs) set at 95%. The ORs were adjusted for known predictors of multimorbidity, including age, menopausal hormone therapy, education, ethnicity, self-reported loneliness, living alone, body mass index, smoking habits, nutritional risk, social participation, and physical activity.</div></div><div><h3>Result(s)</h3><div>A total of 12,339 postmenopausal participants were included, of whom 374 (3.0%) experienced POI and 1,396 (11.3%) experienced early menopause. The prevalence rates of multimorbidity were 64.8% and 51.1% among those with POI and early menopause, respectively. In contrast, only 43.9% of individuals with average age of menopause (age, 46–55 years) had multimorbidity. The OR for multimorbidity in the POI population was 2.5 (95% CI, 2.0–3.1) compared with that in individuals who had the average age of menopause. This relationship was maintained after adjustment for confounders (adjusted OR [aOR], 2.0; 95% CI, 1.5–2.5). The prevalence of severe multimorbidity was also double in the POI group compared with that in the average age group (39.2% vs. 21.1%). There were significantly increased risks of ischemic heart disease (aOR, 2.8; 95% CI, 1.7–4.7), gastric ulcers (aOR, 1.6; 95% CI, 1.1–2.3), and osteoporosis (aOR, 1.6; 95% CI, 1.2–2.1) in the POI group.</div></div><div><h3>Conclusion(s)</h3><div>Individuals with POI and early menopause experience increased multimorbidity compared with those undergoing menopause at an average age. This trend persists even after adjusting for significant multimorbidity risk factors.</div></div><div><div>Asociación entre insuficiencia ovárica primaria y incremento en la multi","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 289-299"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.09.006
Philippa Ralph M.B.B.S. , Mohammed Mahoud M.B.B.S. , Daniel Schlager M.B.B.S. , Wai Gin Lee M.B.B.S. , Raheala Wafa M.Sc. , Elizabeth Williamson M.Sc. , Gary Butler M.D. , David Ralph M.B.B.S. , Philippa Sangster M.B.B.S.
<div><h3>Objective</h3><div>Increasing numbers of adolescents with gender dysphoria start gonadotropin-releasing hormone agonists to halt puberty, minimizing psychological distress. The uncertainty of long-term effects of this medication, and the subsequent likelihood of accessing gender-affirming hormone treatment, highlights the importance of fertility preservation before starting hormone treatment. We investigated the take-up, hormonal profile, and sperm quality in adolescents undergoing fertility preservation via cryopreservation by masturbation or surgical sperm retrieval, before starting hormonal therapy.</div></div><div><h3>Design</h3><div>Data were prospectively maintained from a tertiary UK-based hospital. A total of 122 people <19 years, mean age 15.2 ± 1.7 years, referred by gender clinics and general practitioners, were included in this cohort study.</div></div><div><h3>Subjects</h3><div>Participants were counseled for fertility preservation, and serum testosterone, follicle-stimulating hormone, and luteinizing hormone levels were recorded before providing semen samples.</div></div><div><h3>Exposure</h3><div>Masturbation semen samples were classified as normal (>15 mil/mL), oligozoospermia (1–15 mil/mL), cryptozoospermia (<1 mil/mL), or azoospermia. If the sample was insufficient or the person was unwilling to masturbate, surgical sperm retrieval was offered in a stepwise manner using electroejaculation, testicular sperm extraction (TESE) ± microdissection testicular sperm extraction (mTESE).</div></div><div><h3>Main Outcome Measures</h3><div>Quality of semen produced by participants, via masturbation or surgical sperm retrieval, was analyzed to determine if it was good enough to cryopreserve for future fertility use.</div></div><div><h3>Results</h3><div>Of 122 participants, 23 (19%) declined sample storage. In the masturbation group (average age, 16.3 years), 78 people produced 106 samples. Of 106 samples, 86 were stored—43.7% were normospermic, 35.9% oligozoospermic, 8.7% cryptozoospermic, and 11.7% azoospermic. Overall, semen parameters varied but were generally abnormal, illustrated by only 43.7% of the masturbation samples produced being normospermic. For surgical sperm retrieval subjects (average age, 15.2 years), electroejaculation was successful in 4 of 21 people, whereas the rest proceeded with TESE/mTESE. Encouragingly, 16 of 21 subjects had an average of 5 vials stored, and all participants had a testosterone level >8 nmol/L. Semen parameters in this subcohort were poor but possibly adequate for intracytoplasmic sperm injection.</div></div><div><h3>Conclusions</h3><div>In this large database of transgender girls referred for fertility preservation in the United Kingdom, fertility preservation is possible, even with those unwilling to masturbate. Long-term data are required to check the health of these gametes, observing live birth rates using these preserved gametes.</div></div><div><div>Recolección de datos sob
{"title":"United Kingdom data collection of semen quality in transgender adolescent females seeking fertility preservation","authors":"Philippa Ralph M.B.B.S. , Mohammed Mahoud M.B.B.S. , Daniel Schlager M.B.B.S. , Wai Gin Lee M.B.B.S. , Raheala Wafa M.Sc. , Elizabeth Williamson M.Sc. , Gary Butler M.D. , David Ralph M.B.B.S. , Philippa Sangster M.B.B.S.","doi":"10.1016/j.fertnstert.2024.09.006","DOIUrl":"10.1016/j.fertnstert.2024.09.006","url":null,"abstract":"<div><h3>Objective</h3><div>Increasing numbers of adolescents with gender dysphoria start gonadotropin-releasing hormone agonists to halt puberty, minimizing psychological distress. The uncertainty of long-term effects of this medication, and the subsequent likelihood of accessing gender-affirming hormone treatment, highlights the importance of fertility preservation before starting hormone treatment. We investigated the take-up, hormonal profile, and sperm quality in adolescents undergoing fertility preservation via cryopreservation by masturbation or surgical sperm retrieval, before starting hormonal therapy.</div></div><div><h3>Design</h3><div>Data were prospectively maintained from a tertiary UK-based hospital. A total of 122 people <19 years, mean age 15.2 ± 1.7 years, referred by gender clinics and general practitioners, were included in this cohort study.</div></div><div><h3>Subjects</h3><div>Participants were counseled for fertility preservation, and serum testosterone, follicle-stimulating hormone, and luteinizing hormone levels were recorded before providing semen samples.</div></div><div><h3>Exposure</h3><div>Masturbation semen samples were classified as normal (>15 mil/mL), oligozoospermia (1–15 mil/mL), cryptozoospermia (<1 mil/mL), or azoospermia. If the sample was insufficient or the person was unwilling to masturbate, surgical sperm retrieval was offered in a stepwise manner using electroejaculation, testicular sperm extraction (TESE) ± microdissection testicular sperm extraction (mTESE).</div></div><div><h3>Main Outcome Measures</h3><div>Quality of semen produced by participants, via masturbation or surgical sperm retrieval, was analyzed to determine if it was good enough to cryopreserve for future fertility use.</div></div><div><h3>Results</h3><div>Of 122 participants, 23 (19%) declined sample storage. In the masturbation group (average age, 16.3 years), 78 people produced 106 samples. Of 106 samples, 86 were stored—43.7% were normospermic, 35.9% oligozoospermic, 8.7% cryptozoospermic, and 11.7% azoospermic. Overall, semen parameters varied but were generally abnormal, illustrated by only 43.7% of the masturbation samples produced being normospermic. For surgical sperm retrieval subjects (average age, 15.2 years), electroejaculation was successful in 4 of 21 people, whereas the rest proceeded with TESE/mTESE. Encouragingly, 16 of 21 subjects had an average of 5 vials stored, and all participants had a testosterone level >8 nmol/L. Semen parameters in this subcohort were poor but possibly adequate for intracytoplasmic sperm injection.</div></div><div><h3>Conclusions</h3><div>In this large database of transgender girls referred for fertility preservation in the United Kingdom, fertility preservation is possible, even with those unwilling to masturbate. Long-term data are required to check the health of these gametes, observing live birth rates using these preserved gametes.</div></div><div><div>Recolección de datos sob","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 313-321"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.09.015
Rachel Solmonovich M.D. , Insaf Kouba M.D. , Frank I. Jackson D.O. , Alejandro Alvarez M.P.H. , Randi H. Goldman M.D. , Gabriel San Roman M.D. , Matthew J. Blitz M.D., M.B.A.
<div><h3>Objective</h3><div>To determine whether an association exists between in vitro fertilization (IVF) and severe maternal morbidity among low-risk pregnant patients.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Low-risk pregnant patients who delivered between January 2019 and December 2022. Low-risk was defined as having an obstetric comorbidity index score of 0.</div></div><div><h3>Exposure</h3><div>In vitro fertilization.</div></div><div><h3>Main Outcome Measure(s)</h3><div>The primary outcome (dependent variable) was any severe maternal morbidity. The secondary outcome was the need for a cesarean delivery. A modified Poisson regression with robust error variance was used to model the probability of severe maternal morbidity as a function of IVF. Risk ratios and their associated 95% confidence intervals (CIs) were computed. An α value of 0.05 was considered statistically significant.</div></div><div><h3>Result(s)</h3><div>A total of 39,668 pregnancies were included for analysis, and 454 (1.1%) were conceived by IVF. The overall severe maternal morbidity rate was 2.4% (n = 949), with the most common indicator being blood transfusion. The overall cesarean delivery rate was 18.8% (n = 7,459). On modified Poisson regression, IVF-conceived pregnancies were associated with 2.56 times the risk of severe maternal morbidity (95% CI, 1.73–3.79) and 1.54 times the risk of having a cesarean delivery (95% CI, 1.37–1.74) compared with non-IVF pregnancies.</div></div><div><h3>Conclusion(s)</h3><div>In vitro fertilization is associated with higher rates of severe maternal morbidity, primarily the need for a blood transfusion, and cesarean delivery in low-risk pregnancies without major comorbidities. Recognizing this association allows healthcare providers to implement proactive measures for better monitoring and tailored postpartum care.</div></div><div><div>Asociación Entre La Fecundación in Vitro Y Morbilidad Materna Severa en Pacientes de Bajo Riesgo Sin Comorbilidades</div></div><div><h3>Objetivo</h3><div>Determinar si existe asociación entre la fecundación in vitro (FIV) y la morbilidad materna severa en pacientes gestantes de bajo riesgo.</div></div><div><h3>Diseño</h3><div>Estudio retrospectivo de cohortes.</div></div><div><h3>Entorno</h3><div>Sistema sanitario universitario.</div></div><div><h3>Paciente(s)</h3><div>Pacientes gestantes de bajo riesgo que dieron a luz entre junio de 2019 y diciembre de 2022. Se definió bajo riesgo cuando la puntuación del índice de comorbilidad obstétrico era de 0.</div></div><div><h3>Intervención(es)</h3><div>Fecundación in vitro.</div></div><div><h3>Medida principal de resultado</h3><div>El resultado principal (variable dependiente) fue cualquier morbilidad materna severa. El objetivo secundario fue la necesidad de nacimiento por cesárea. El modelo utilizado para calcular la probabilidad de morbilidad materna grave en función de la FIV fue una regresión de
{"title":"Association of in vitro fertilization with severe maternal morbidity in low-risk patients without comorbidities","authors":"Rachel Solmonovich M.D. , Insaf Kouba M.D. , Frank I. Jackson D.O. , Alejandro Alvarez M.P.H. , Randi H. Goldman M.D. , Gabriel San Roman M.D. , Matthew J. Blitz M.D., M.B.A.","doi":"10.1016/j.fertnstert.2024.09.015","DOIUrl":"10.1016/j.fertnstert.2024.09.015","url":null,"abstract":"<div><h3>Objective</h3><div>To determine whether an association exists between in vitro fertilization (IVF) and severe maternal morbidity among low-risk pregnant patients.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Low-risk pregnant patients who delivered between January 2019 and December 2022. Low-risk was defined as having an obstetric comorbidity index score of 0.</div></div><div><h3>Exposure</h3><div>In vitro fertilization.</div></div><div><h3>Main Outcome Measure(s)</h3><div>The primary outcome (dependent variable) was any severe maternal morbidity. The secondary outcome was the need for a cesarean delivery. A modified Poisson regression with robust error variance was used to model the probability of severe maternal morbidity as a function of IVF. Risk ratios and their associated 95% confidence intervals (CIs) were computed. An α value of 0.05 was considered statistically significant.</div></div><div><h3>Result(s)</h3><div>A total of 39,668 pregnancies were included for analysis, and 454 (1.1%) were conceived by IVF. The overall severe maternal morbidity rate was 2.4% (n = 949), with the most common indicator being blood transfusion. The overall cesarean delivery rate was 18.8% (n = 7,459). On modified Poisson regression, IVF-conceived pregnancies were associated with 2.56 times the risk of severe maternal morbidity (95% CI, 1.73–3.79) and 1.54 times the risk of having a cesarean delivery (95% CI, 1.37–1.74) compared with non-IVF pregnancies.</div></div><div><h3>Conclusion(s)</h3><div>In vitro fertilization is associated with higher rates of severe maternal morbidity, primarily the need for a blood transfusion, and cesarean delivery in low-risk pregnancies without major comorbidities. Recognizing this association allows healthcare providers to implement proactive measures for better monitoring and tailored postpartum care.</div></div><div><div>Asociación Entre La Fecundación in Vitro Y Morbilidad Materna Severa en Pacientes de Bajo Riesgo Sin Comorbilidades</div></div><div><h3>Objetivo</h3><div>Determinar si existe asociación entre la fecundación in vitro (FIV) y la morbilidad materna severa en pacientes gestantes de bajo riesgo.</div></div><div><h3>Diseño</h3><div>Estudio retrospectivo de cohortes.</div></div><div><h3>Entorno</h3><div>Sistema sanitario universitario.</div></div><div><h3>Paciente(s)</h3><div>Pacientes gestantes de bajo riesgo que dieron a luz entre junio de 2019 y diciembre de 2022. Se definió bajo riesgo cuando la puntuación del índice de comorbilidad obstétrico era de 0.</div></div><div><h3>Intervención(es)</h3><div>Fecundación in vitro.</div></div><div><h3>Medida principal de resultado</h3><div>El resultado principal (variable dependiente) fue cualquier morbilidad materna severa. El objetivo secundario fue la necesidad de nacimiento por cesárea. El modelo utilizado para calcular la probabilidad de morbilidad materna grave en función de la FIV fue una regresión de ","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 262-269"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.10.051
Rudi Campo M.D. , Evy Gillet M.D. , Stephan Gordts M.D. , Marion Valkenburg M.D. , Helena Van Kerrebroeck M.D. , Alessa Sugihara M.D. , Istvan Argay M.D. , Panayiotis Tanos M.D.
<div><h3>Objective</h3><div>To study the value of hysteroscopic cytoreductive surgery for adenomyotic lesions to improve reproductive outcomes. We describe a feasible and novel minimal invasive stepwise approach, which did not result in postoperative adhesion formation and restored favorable reproductive outcomes.</div></div><div><h3>Design</h3><div>Video article.</div></div><div><h3>Subjects</h3><div>Patients aged <37 years, diagnosed with adenomyotic lesions by ultrasound and/or magnetic resonance imaging, who after a minimum of 6 months of medical treatment (gonadotrophin releasing hormone agonist or dienogest) failed to conceive with a minimum of two embryo transfer cycles of high-quality blastocysts were included.</div></div><div><h3>Exposure</h3><div>The procedure was performed under conscious sedation, level 3b in an ambulatory surgical center. All patients received hormonal suppressive treatment (Dienogest 2 mgr per day or Triptoreline 3.75 mgr. IM once a month). Institutional Review Board approval and patient consent had been received for the study. The surgical steps included the following:<ul><li><span>•</span><span><div>Identification of the inner myometrial lesion by combined ultrasonographic-hysteroscopic examination.</div></span></li><li><span>•</span><span><div>Incision of the lesion at the midline with a 15-Fr bipolar mini-resectoscope until the pathological adenomyotic tissue was totally removed. In contrast to ultrasound and magnetic resonance imaging, hysteroscopy can visualize a clear tissue structure difference between the adenomyotic fibrotic lesion and the surrounding healthy myometrium. Intermittent transvaginal ultrasound is mandatory to control the myometrial security zone, which should not be <1 cm.</div></span></li><li><span>•</span><span><div>Removal of the side wall pathological tissue, using the same hysteroscopic visual references, aiming to avoid thermal injury to the surrounding healthy myometrial layer.</div></span></li><li><span>•</span><span><div>Application of hyaluronic acid antiadhesive barrier gel under hysteroscopic vision.</div></span></li><li><span>•</span><span><div>Second-look hysteroscopy was scheduled after 8 weeks.</div></span></li></ul></div></div><div><h3>Main Outcome Measure(s)</h3><div>Feasibility, reproductive outcomes, and complications (adhesions and placental disorders).</div></div><div><h3>Result(s)</h3><div>Fifteen patients underwent surgery and had histological confirmation of adenomyosis. Second-look hysteroscopy was possible in 13 of 15 women (2 spontaneous pregnancies) with reassuring postoperative results, showing only mild lateral wall adhesions in three cases. Pregnancy was registered in 12 women: one early miscarriage; seven ongoing pregnancies; and four deliveries of healthy infants with normal birth weight and no placenta-related complications.</div></div><div><h3>Conclusion</h3><div>(s): In contrast to the current beliefs, mini hysteroscopy can identify and selectively r
{"title":"Stepwise approach of hysteroscopic cytoreductive surgery for adenomyosis in patients with recurrent implantation failure","authors":"Rudi Campo M.D. , Evy Gillet M.D. , Stephan Gordts M.D. , Marion Valkenburg M.D. , Helena Van Kerrebroeck M.D. , Alessa Sugihara M.D. , Istvan Argay M.D. , Panayiotis Tanos M.D.","doi":"10.1016/j.fertnstert.2024.10.051","DOIUrl":"10.1016/j.fertnstert.2024.10.051","url":null,"abstract":"<div><h3>Objective</h3><div>To study the value of hysteroscopic cytoreductive surgery for adenomyotic lesions to improve reproductive outcomes. We describe a feasible and novel minimal invasive stepwise approach, which did not result in postoperative adhesion formation and restored favorable reproductive outcomes.</div></div><div><h3>Design</h3><div>Video article.</div></div><div><h3>Subjects</h3><div>Patients aged <37 years, diagnosed with adenomyotic lesions by ultrasound and/or magnetic resonance imaging, who after a minimum of 6 months of medical treatment (gonadotrophin releasing hormone agonist or dienogest) failed to conceive with a minimum of two embryo transfer cycles of high-quality blastocysts were included.</div></div><div><h3>Exposure</h3><div>The procedure was performed under conscious sedation, level 3b in an ambulatory surgical center. All patients received hormonal suppressive treatment (Dienogest 2 mgr per day or Triptoreline 3.75 mgr. IM once a month). Institutional Review Board approval and patient consent had been received for the study. The surgical steps included the following:<ul><li><span>•</span><span><div>Identification of the inner myometrial lesion by combined ultrasonographic-hysteroscopic examination.</div></span></li><li><span>•</span><span><div>Incision of the lesion at the midline with a 15-Fr bipolar mini-resectoscope until the pathological adenomyotic tissue was totally removed. In contrast to ultrasound and magnetic resonance imaging, hysteroscopy can visualize a clear tissue structure difference between the adenomyotic fibrotic lesion and the surrounding healthy myometrium. Intermittent transvaginal ultrasound is mandatory to control the myometrial security zone, which should not be <1 cm.</div></span></li><li><span>•</span><span><div>Removal of the side wall pathological tissue, using the same hysteroscopic visual references, aiming to avoid thermal injury to the surrounding healthy myometrial layer.</div></span></li><li><span>•</span><span><div>Application of hyaluronic acid antiadhesive barrier gel under hysteroscopic vision.</div></span></li><li><span>•</span><span><div>Second-look hysteroscopy was scheduled after 8 weeks.</div></span></li></ul></div></div><div><h3>Main Outcome Measure(s)</h3><div>Feasibility, reproductive outcomes, and complications (adhesions and placental disorders).</div></div><div><h3>Result(s)</h3><div>Fifteen patients underwent surgery and had histological confirmation of adenomyosis. Second-look hysteroscopy was possible in 13 of 15 women (2 spontaneous pregnancies) with reassuring postoperative results, showing only mild lateral wall adhesions in three cases. Pregnancy was registered in 12 women: one early miscarriage; seven ongoing pregnancies; and four deliveries of healthy infants with normal birth weight and no placenta-related complications.</div></div><div><h3>Conclusion</h3><div>(s): In contrast to the current beliefs, mini hysteroscopy can identify and selectively r","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 370-372"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"To be frank: is it time to say goodbye to Abbe-McIndoe and Vecchietti?","authors":"Marisa Imbroane B.S. , Allison Bosch M.D. , Elliott G. Richards M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.12.004","DOIUrl":"10.1016/j.fertnstert.2024.12.004","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 251-252"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.08.331
Vasanti Jadva Ph.D. , Catherine Jones Ph.D. , Sophie Zadeh Ph.D.
<div><h3>Objective</h3><div>To understand how the Donor Conception Identity Questionnaire (DCIQ) correlates with mental health and explore differences in the DCIQ between donor conceived people who were actively searching for donor connections to those who were not and those who had found their donor connections to those who had not.</div></div><div><h3>Design</h3><div>Cross-sectional survey.</div></div><div><h3>Subjects</h3><div>A total of 88 donor conceived adults ranging in age from 18 to 70 (mean, 34.27 years; median, 31 years). A total of 39 participants were actively searching for their donor connections, and 49 were not.</div></div><div><h3>Exposure</h3><div>Donor conception identity was measured using a questionnaire and scores were correlated with existing measures of mental health.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Participants completed the DCIQ and measures of well-being, satisfaction with life, identity, pride, and stigma.</div></div><div><h3>Result(s)</h3><div>Factor analysis of items from the DCIQ identified four domains: concern and preoccupation; internalized stigma; pride and acceptance; and openness and understanding. The identified factors correlated with scales of psychological and social well-being. Active searchers scored higher than non-active searchers on “concern and preoccupation” and “internalized stigma”. Donor conceived individuals who had found their donor connections scored lower on “internalized stigma” and higher on “openness and understanding” compared with those who had not found their donor connections.</div></div><div><h3>Conclusion(s)</h3><div>The findings of the present study show that scores on the DCIQ correlate with existing measures of psychological and social well-being. Furthermore, donor conceived individuals searching for their donor connections differ from those not actively searching on key domains of the DCIQ. Implications for future avenues of study and support for donor conceived people are discussed.</div></div><div><div>Cuestionario de Identidad de Concepción por donante: asociaciones con la salud mental y la búsqueda y el encuentro de conexiones con donantes</div></div><div><h3>Objetivo</h3><div>comprender cómo el Cuestionario de Identidad de Concepción por Donante (DCIQ) se correlaciona con la salud mental y explorar las diferencias en el DCIQ entre las personas concebidas por donación que estaban buscando activamente conexiones con donantes y las que no, así como aquellas que habían encontrado sus conexiones con donantes y las que no.</div></div><div><h3>Diseño</h3><div>una encuesta transversal.</div></div><div><h3>Lugar</h3><div>encuesta realizada en línea en el Reino Unido.</div></div><div><h3>Paciente(s)</h3><div>Un total de 88 adultos concebidos por donación, con edades comprendidas entre los 18 y los 70 años (media, 34.27 años; mediana, 31 años). Un total de 39 pacientes estaban activamente buscado sus conexiones con donantes y 49, no.</div></div><div><h3>Intervenci
{"title":"The Donor Conception Identity Questionnaire: associations with mental health and searching for and finding donor connections","authors":"Vasanti Jadva Ph.D. , Catherine Jones Ph.D. , Sophie Zadeh Ph.D.","doi":"10.1016/j.fertnstert.2024.08.331","DOIUrl":"10.1016/j.fertnstert.2024.08.331","url":null,"abstract":"<div><h3>Objective</h3><div>To understand how the Donor Conception Identity Questionnaire (DCIQ) correlates with mental health and explore differences in the DCIQ between donor conceived people who were actively searching for donor connections to those who were not and those who had found their donor connections to those who had not.</div></div><div><h3>Design</h3><div>Cross-sectional survey.</div></div><div><h3>Subjects</h3><div>A total of 88 donor conceived adults ranging in age from 18 to 70 (mean, 34.27 years; median, 31 years). A total of 39 participants were actively searching for their donor connections, and 49 were not.</div></div><div><h3>Exposure</h3><div>Donor conception identity was measured using a questionnaire and scores were correlated with existing measures of mental health.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Participants completed the DCIQ and measures of well-being, satisfaction with life, identity, pride, and stigma.</div></div><div><h3>Result(s)</h3><div>Factor analysis of items from the DCIQ identified four domains: concern and preoccupation; internalized stigma; pride and acceptance; and openness and understanding. The identified factors correlated with scales of psychological and social well-being. Active searchers scored higher than non-active searchers on “concern and preoccupation” and “internalized stigma”. Donor conceived individuals who had found their donor connections scored lower on “internalized stigma” and higher on “openness and understanding” compared with those who had not found their donor connections.</div></div><div><h3>Conclusion(s)</h3><div>The findings of the present study show that scores on the DCIQ correlate with existing measures of psychological and social well-being. Furthermore, donor conceived individuals searching for their donor connections differ from those not actively searching on key domains of the DCIQ. Implications for future avenues of study and support for donor conceived people are discussed.</div></div><div><div>Cuestionario de Identidad de Concepción por donante: asociaciones con la salud mental y la búsqueda y el encuentro de conexiones con donantes</div></div><div><h3>Objetivo</h3><div>comprender cómo el Cuestionario de Identidad de Concepción por Donante (DCIQ) se correlaciona con la salud mental y explorar las diferencias en el DCIQ entre las personas concebidas por donación que estaban buscando activamente conexiones con donantes y las que no, así como aquellas que habían encontrado sus conexiones con donantes y las que no.</div></div><div><h3>Diseño</h3><div>una encuesta transversal.</div></div><div><h3>Lugar</h3><div>encuesta realizada en línea en el Reino Unido.</div></div><div><h3>Paciente(s)</h3><div>Un total de 88 adultos concebidos por donación, con edades comprendidas entre los 18 y los 70 años (media, 34.27 años; mediana, 31 años). Un total de 39 pacientes estaban activamente buscado sus conexiones con donantes y 49, no.</div></div><div><h3>Intervenci","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 322-332"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.08.353
Stefano Palomba M.D., Donatella Caserta M.D.
{"title":"Follitropin delta: is further evidence needed?","authors":"Stefano Palomba M.D., Donatella Caserta M.D.","doi":"10.1016/j.fertnstert.2024.08.353","DOIUrl":"10.1016/j.fertnstert.2024.08.353","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Page 373"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><h3>Objective</h3><div>To assess changes in morphology and size of endometriomas during pregnancy and after delivery.</div></div><div><h3>Design</h3><div>This was a prospective observational cohort study performed during 2013–2024 at a tertiary care center (Ultrasound Unit, Department of Obstetrics and Gynecology, Skane University Hospital, Malmo, Sweden). Women were offered repeated ultrasound examinations every month during pregnancy and thereafter at 3 and 12 months after delivery. Ultrasound examinations were performed either transvaginally or transabdominally depending on the gestational week and assessability of the ovaries.</div></div><div><h3>Subjects</h3><div>Pregnant women with an ovarian cyst suggestive of endometrioma based on subjective assessment were eligible and those with the pregnancy that continued beyond gestational age of 22 weeks were included. In total, 57 women were included.</div></div><div><h3>Exposure</h3><div>Pregnancy.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Changes in morphology (cyst type, cyst content, and signs of decidualization) and size of the endometrioma and the largest solid component were assessed during follow-up ultrasound examinations.</div></div><div><h3>Result(s)</h3><div>During pregnancy, endometriomas changed in morphology in 42/57 women (74%; 95% confidence interval [CI], 60–84) and decreased in size in 42/57 women (74%; 95% CI, 60–84). Decidualization of endometrioma was observed in 33/57 women (58%; 95% CI, 44–71) and was detected first time at gestational age of 17 weeks (median, interquartile range, 15–22; range, 6–29). The size of endometriomas decreased although the size of solid components increased from gestational age of 22<sup>+0</sup> weeks. Signs of decidualization disappeared after delivery.</div></div><div><h3>Conclusion(s)</h3><div>Three out of four endometriomas undergo morphological changes during pregnancy. Decidualized endometrioma may mimic borderline malignancy, however, changes regress after delivery. Knowing the natural behavior of endometriomas during pregnancy is crucial to reducing the risk of misclassification of endometriomas as malignant masses. Follow-up ultrasound examination after delivery helps to reassure the benign nature of the cyst.</div></div><div><div>Cambios morfológicos de los endometriomas durante el embarazo y después del parto detectados mediante ecografía.</div></div><div><h3>Objetivo</h3><div>Evaluar los cambios en la morfología y el tamaño de los endometriomas durante el embarazo y después del parto.</div></div><div><h3>Diseño</h3><div>Estudio observacional prospectivo de cohorte realizado entre 2013 y 2024 en un centro de atención terciaria (Unidad de Ultrasonido, Departamento de Obstetricia y Ginecología, Hospital Universitario de Skane, Malmö, Suecia). A las mujeres se les ofrecieron exámenes repetidos de ultrasonido cada mes durante el embarazo y posteriormente a los 3 y 12 meses tras el parto. Las ecografías se realizaron por vía
{"title":"Morphological changes of endometriomas during pregnancy and after delivery detected using ultrasound","authors":"Sofie Orlov M.D. , Povilas Sladkevicius M.D., Ph.D. , Isis Rivano Eckerdal M.D. , Ligita Jokubkiene M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.08.355","DOIUrl":"10.1016/j.fertnstert.2024.08.355","url":null,"abstract":"<div><h3>Objective</h3><div>To assess changes in morphology and size of endometriomas during pregnancy and after delivery.</div></div><div><h3>Design</h3><div>This was a prospective observational cohort study performed during 2013–2024 at a tertiary care center (Ultrasound Unit, Department of Obstetrics and Gynecology, Skane University Hospital, Malmo, Sweden). Women were offered repeated ultrasound examinations every month during pregnancy and thereafter at 3 and 12 months after delivery. Ultrasound examinations were performed either transvaginally or transabdominally depending on the gestational week and assessability of the ovaries.</div></div><div><h3>Subjects</h3><div>Pregnant women with an ovarian cyst suggestive of endometrioma based on subjective assessment were eligible and those with the pregnancy that continued beyond gestational age of 22 weeks were included. In total, 57 women were included.</div></div><div><h3>Exposure</h3><div>Pregnancy.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Changes in morphology (cyst type, cyst content, and signs of decidualization) and size of the endometrioma and the largest solid component were assessed during follow-up ultrasound examinations.</div></div><div><h3>Result(s)</h3><div>During pregnancy, endometriomas changed in morphology in 42/57 women (74%; 95% confidence interval [CI], 60–84) and decreased in size in 42/57 women (74%; 95% CI, 60–84). Decidualization of endometrioma was observed in 33/57 women (58%; 95% CI, 44–71) and was detected first time at gestational age of 17 weeks (median, interquartile range, 15–22; range, 6–29). The size of endometriomas decreased although the size of solid components increased from gestational age of 22<sup>+0</sup> weeks. Signs of decidualization disappeared after delivery.</div></div><div><h3>Conclusion(s)</h3><div>Three out of four endometriomas undergo morphological changes during pregnancy. Decidualized endometrioma may mimic borderline malignancy, however, changes regress after delivery. Knowing the natural behavior of endometriomas during pregnancy is crucial to reducing the risk of misclassification of endometriomas as malignant masses. Follow-up ultrasound examination after delivery helps to reassure the benign nature of the cyst.</div></div><div><div>Cambios morfológicos de los endometriomas durante el embarazo y después del parto detectados mediante ecografía.</div></div><div><h3>Objetivo</h3><div>Evaluar los cambios en la morfología y el tamaño de los endometriomas durante el embarazo y después del parto.</div></div><div><h3>Diseño</h3><div>Estudio observacional prospectivo de cohorte realizado entre 2013 y 2024 en un centro de atención terciaria (Unidad de Ultrasonido, Departamento de Obstetricia y Ginecología, Hospital Universitario de Skane, Malmö, Suecia). A las mujeres se les ofrecieron exámenes repetidos de ultrasonido cada mes durante el embarazo y posteriormente a los 3 y 12 meses tras el parto. Las ecografías se realizaron por vía ","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 211-220"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.08.354
Hortense Everaere M.D. , Virginie Simon M.D. , Anne Bachelot M.D., Ph.D. , Maxime Leroy B.S. , Christine Decanter M.D. , Didier Dewailly M.D. , Sophie Catteau-Jonard M.D., Ph.D. , Geoffroy Robin M.D.
<div><h3>Objective</h3><div>To compare the ongoing pregnancy rate per initiated cycle between patients with functional hypothalamic amenorrhea (FHA) and patients with congenital hypogonadotropic hypogonadism (CHH) treated with pulsatile gonadotropin-releasing hormone (GnRH) administration.</div></div><div><h3>Design</h3><div>Retrospective monocentric cohort study conducted at the University Hospital of Lille from 2004 to 2022.</div></div><div><h3>Subjects</h3><div>A total of 141 patients diagnosed with central suprapituitary amenorrhea during infertility evaluation and subsequently treated with pulsatile GnRH therapy. 111 and 30 patients were diagnosed with FHA or CHH, respectively.</div></div><div><h3>Exposure</h3><div>Pulsatile GnRH administration.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Ongoing pregnancy rate per initiated cycle.</div></div><div><h3>Result(s)</h3><div>Ongoing pregnancy rates per initiated cycle were comparable between groups: 21.5% in the FHA group vs. 22% in the CHH group. Comparison of baseline characteristics showed a more pronounced follicle-stimulating hormone (FSH) deficiency in patients with CHH than in those with FHA: 2.55 (0.6–4.92) vs. 4.80 (3.90–5.70) UI/L. Within the CHH group, basal FSH level was positively associated with the occurrence of ongoing pregnancies (odds ratio, 1.57; 95% confidence interval, 1.11–2.22). In the CHH group, the duration of treatment was higher than in the FHA group: 23.59 (± 8.02) vs. 18.16 (± 7.66) days.</div></div><div><h3>Conclusion(s)</h3><div>The baseline FSH level is lower in patients with CHH than in patients with FHA. The lower the FSH, the lower the chance of pregnancy in patients with CHH. These patients also require more days of GnRH administration. However, the rate of ongoing pregnancies is comparable between the two groups.</div></div><div><div>Terapia hormonal pulsátil liberadora de gonadotropina: Comparación de la eficacia entre la amenorrea hipotalámica funcional y el hipogonadismo hipogonadotrópico congénito</div></div><div><h3>Objetivo</h3><div>Comparar la tasa de embarazo en curso por ciclo iniciado entre pacientes con amenorrea hipotalámica funcional (AHF) y pacientes con hipogonadismo hipogonadotrópico congénito (HHC) tratadas con administración pulsátil de hormona liberadora de gonadotropina (GnRH).</div></div><div><h3>Diseño</h3><div>Estudio de cohorte retrospectivo monocéntrico llevado a cabo en la Universidad Hospital de Lille desde el 2004 al 2022.</div></div><div><h3>Escenario</h3><div>Universidad Hospital de Lille, Departamento de Ginecología Endocrina.</div></div><div><h3>Paciente(s)</h3><div>Un total de 141 pacientes diagnosticas con amenorrea suprapituitaria central durante la evaluación por infertilidad y subsecuentemente tratadas con terapía pulsátil de GnRH. 111 y 30 pacientes fueron diagnosticas con AHF y HHC, respectivamente.</div></div><div><h3>Intervención(es)</h3><div>Administración pulsátil de GnRH.</div></div><div><h3>Medida de result
{"title":"Pulsatile gonadotropin-releasing hormone therapy: comparison of efficacy between functional hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism","authors":"Hortense Everaere M.D. , Virginie Simon M.D. , Anne Bachelot M.D., Ph.D. , Maxime Leroy B.S. , Christine Decanter M.D. , Didier Dewailly M.D. , Sophie Catteau-Jonard M.D., Ph.D. , Geoffroy Robin M.D.","doi":"10.1016/j.fertnstert.2024.08.354","DOIUrl":"10.1016/j.fertnstert.2024.08.354","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the ongoing pregnancy rate per initiated cycle between patients with functional hypothalamic amenorrhea (FHA) and patients with congenital hypogonadotropic hypogonadism (CHH) treated with pulsatile gonadotropin-releasing hormone (GnRH) administration.</div></div><div><h3>Design</h3><div>Retrospective monocentric cohort study conducted at the University Hospital of Lille from 2004 to 2022.</div></div><div><h3>Subjects</h3><div>A total of 141 patients diagnosed with central suprapituitary amenorrhea during infertility evaluation and subsequently treated with pulsatile GnRH therapy. 111 and 30 patients were diagnosed with FHA or CHH, respectively.</div></div><div><h3>Exposure</h3><div>Pulsatile GnRH administration.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Ongoing pregnancy rate per initiated cycle.</div></div><div><h3>Result(s)</h3><div>Ongoing pregnancy rates per initiated cycle were comparable between groups: 21.5% in the FHA group vs. 22% in the CHH group. Comparison of baseline characteristics showed a more pronounced follicle-stimulating hormone (FSH) deficiency in patients with CHH than in those with FHA: 2.55 (0.6–4.92) vs. 4.80 (3.90–5.70) UI/L. Within the CHH group, basal FSH level was positively associated with the occurrence of ongoing pregnancies (odds ratio, 1.57; 95% confidence interval, 1.11–2.22). In the CHH group, the duration of treatment was higher than in the FHA group: 23.59 (± 8.02) vs. 18.16 (± 7.66) days.</div></div><div><h3>Conclusion(s)</h3><div>The baseline FSH level is lower in patients with CHH than in patients with FHA. The lower the FSH, the lower the chance of pregnancy in patients with CHH. These patients also require more days of GnRH administration. However, the rate of ongoing pregnancies is comparable between the two groups.</div></div><div><div>Terapia hormonal pulsátil liberadora de gonadotropina: Comparación de la eficacia entre la amenorrea hipotalámica funcional y el hipogonadismo hipogonadotrópico congénito</div></div><div><h3>Objetivo</h3><div>Comparar la tasa de embarazo en curso por ciclo iniciado entre pacientes con amenorrea hipotalámica funcional (AHF) y pacientes con hipogonadismo hipogonadotrópico congénito (HHC) tratadas con administración pulsátil de hormona liberadora de gonadotropina (GnRH).</div></div><div><h3>Diseño</h3><div>Estudio de cohorte retrospectivo monocéntrico llevado a cabo en la Universidad Hospital de Lille desde el 2004 al 2022.</div></div><div><h3>Escenario</h3><div>Universidad Hospital de Lille, Departamento de Ginecología Endocrina.</div></div><div><h3>Paciente(s)</h3><div>Un total de 141 pacientes diagnosticas con amenorrea suprapituitaria central durante la evaluación por infertilidad y subsecuentemente tratadas con terapía pulsátil de GnRH. 111 y 30 pacientes fueron diagnosticas con AHF y HHC, respectivamente.</div></div><div><h3>Intervención(es)</h3><div>Administración pulsátil de GnRH.</div></div><div><h3>Medida de result","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 270-279"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.fertnstert.2024.09.026
Shunshun Cao M.Sc. , Yangyang Hu M.Sc.
{"title":"From breast cancer to fertility outcomes: increasing understanding of urgent fertility preservation","authors":"Shunshun Cao M.Sc. , Yangyang Hu M.Sc.","doi":"10.1016/j.fertnstert.2024.09.026","DOIUrl":"10.1016/j.fertnstert.2024.09.026","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Page 375"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：